155 related articles for article (PubMed ID: 36807751)
1. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
Kaban N; Harman H
Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
[TBL] [Abstract][Full Text] [Related]
2. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
3. Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.
Burkard T; Vallejo-Yagüe E; Hügle T; Finckh A; Burden AM
BMJ Open; 2022 Mar; 12(3):e056352. PubMed ID: 35292498
[TBL] [Abstract][Full Text] [Related]
4. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
5. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
[TBL] [Abstract][Full Text] [Related]
6. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
7. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.
Schlager L; Loiskandl M; Aletaha D; Radner H
Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305
[TBL] [Abstract][Full Text] [Related]
8. Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort.
Vallejo-Yagüe E; Pfund JN; Burkard T; Clair C; Micheroli R; Möller B; Finckh A; Burden AM
PLoS One; 2022; 17(10):e0275026. PubMed ID: 36264948
[TBL] [Abstract][Full Text] [Related]
9. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
[TBL] [Abstract][Full Text] [Related]
11. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
[TBL] [Abstract][Full Text] [Related]
13. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
[TBL] [Abstract][Full Text] [Related]
14. Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy.
Wallace BI; England BR; Baker JF; Rojas J; Sauer BC; Roul P; Kunkel GA; Braaten TJ; Petro A; Mikuls TR; Cannon GW
ACR Open Rheumatol; 2023 Sep; 5(9):437-442. PubMed ID: 37491906
[TBL] [Abstract][Full Text] [Related]
15. Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives.
Wiemer N; Webster P; Attur M; Yin Y; Sharma T
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv3-iv7. PubMed ID: 37855678
[TBL] [Abstract][Full Text] [Related]
16. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
17. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry.
Koh JH; Lee Y; Kim HA; Kim J; Shin K
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221096363. PubMed ID: 35586514
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Zhao SS; Kearsley-Fleet L; Bosworth A; Watson K; ; Hyrich KL
Rheumatology (Oxford); 2022 Nov; 61(12):4678-4686. PubMed ID: 35357421
[TBL] [Abstract][Full Text] [Related]
19. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
20. Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.
Whittle SL; Glennon V; Johnston RV; Avery JC; Bell JS; Brennan SE; Fong C; Hissaria P; Horgan B; O'Neill S; Pisaniello HL; Trevena L; Whittaker GA; Wluka A; Buchbinder R
Intern Med J; 2022 Oct; 52(10):1799-1805. PubMed ID: 35567366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
